By NewsDesk — Aug. 7, 2025 (America/New York)
Strand Therapeutics, a Boston‑based startup pioneering programmable messenger RNA (mRNA) therapies, closed a $153 million Series B financing round on Thursday, Aug. 7, 2025. The round—led by Swedish investment firm Kinnevik with participation from Regeneron Ventures, ICONIQ, Amgen Ventures, LG Technology Ventures and the family office of former Johnson & Johnson CEO Alex Gorsky—brings Strand’s lifetime fundraising to more than $250 million[1]. Existing investors such as FPV Ventures, Playground Global, Eli Lilly, ANRI and Potentum also doubled down on the company[1].
Why investors are excited
Investors were drawn to Strand’s computationally designed, self‑replicating mRNA technology. Unlike conventional mRNA therapeutics that deliver a pre‑programmed protein and then degrade, Strand’s constructs incorporate logic circuits that control where, when and how long a therapeutic protein is expressed[2]. The company believes this programmable approach can generate potent and durable immune responses while limiting off‑target effects. Investor Christian Scherrer of Kinnevik said the early clinical data demonstrate the platform’s potential to “reshape how we treat disease”[3].
The financing comes amid political headwinds for mRNA research. The U.S. Department of Health and Human Services recently canceled nearly $500 million in mRNA vaccine research funding, prompting questions about the technology’s future[4]. Strand’s CEO Jake Becraft argues that programmable mRNA therapies are distinct from vaccines; they deliver therapeutic proteins inside tumours or specific tissues, rather than inducing systemic immunity. Becraft said the technology’s “future is incredibly bright” despite vaccine‑related controversies[5].
What the funds will support
The Series B proceeds will fuel clinical development of Strand’s lead program, STX‑001, and advance preclinical candidate STX‑003 as well as other pipeline programs:
| Program | Modality/target | Stage & key data | Citation |
| STX‑001 | Self‑replicating mRNA encoding interleukin‑12 (IL‑12) | In Phase 1/2. The therapy injects an IL‑12–expressing mRNA directly into tumors to reprogram the tumor micro‑environment. Early data presented at the 2025 American Society of Clinical Oncology (ASCO) meeting showed complete and metabolic responses, multiple cases of partial response and prolonged disease stabilization with a favorable safety profile[6]. The trial is open to patients whose solid tumors are refractory to checkpoint inhibitors. | [6] |
| STX‑003 | Systemically delivered, tumor‑targeted self‑replicating mRNA carrying IL‑12 | Preclinical. Data presented at the 2025 AACR and ASGCT meetings showed Strand’s programmable circuits can avoid off‑target payload delivery—including liver avoidance—and deliver IL‑12 selectively to tumors[7]. The company calls STX‑003 the world’s first systemically administrable mRNA therapy with tumor targeting and plans to begin dosing patients in 2026. | [7] |
Beyond these candidates, Strand maintains five additional programs, including therapies for non‑small cell lung cancer and blood malignancies[8]. Becraft said the company aims to prove its platform can deliver drugs to a variety of organs—a challenge that has limited many genetic medicines[9].
Advertisement
How programmable mRNA works
Most mRNA therapies deliver a transcript to cells, instructing them to produce a specific protein, and then degrade. Strand’s platform builds on this concept by encoding genetic logic circuits that act like “if–then” statements inside the mRNA molecule. These circuits can sense cellular cues and turn gene expression on or off accordingly. In addition, the company’s self‑replicating RNA persists longer in target tissues, boosting protein production and immune stimulation[2]. The technology also uses circular RNA modalities to further enhance stability[2].
By encoding IL‑12, a potent pro‑inflammatory cytokine produced by macrophages and dendritic cells, STX‑001 aims to reprogram tumors and stimulate a systemic immune response[10]. Unlike recombinant IL‑12 proteins that have produced toxicity in prior trials, the mRNA‑based approach allows controlled, localized expression. Early results show systemic immune activation and anti‑tumor responses even in non‑injected lesions, according to Becraft[11].
Company background and outlook
Founded in 2017 by MIT‑trained synthetic biologists Jake Becraft and Tasuku Kitada, Strand aims to create programmable genetic medicines for cancer, cell therapy, autoimmune disease and beyond[12]. The company received FDA investigational new drug (IND) clearance for STX‑001 in December 2023 and dosed its first patient ahead of the 2024 ASCO meeting[13]. The Series B round follows a $97 million Series A raised in 2022.
With fresh funding and early clinical validation, Strand is poised to scale its technology. Investor Christian Scherrer said he expects the systemic delivery capability to open new disease targets[3]. Becraft added that the team is entering an “exciting period of expansion,” with the potential to transform treatment for cancer and other serious diseases[11].
As the biotech world digests the news, Strand’s ambitious goal is clear: build an operating system for programmable medicines and usher in a future where mRNA isn’t just a vaccine platform but a versatile therapeutic tool.
[1] [2] [3] [6] [7] [10] [11] [12] [13] Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
[4] [5] [8] [9] Strand raises another $153M to make ‘programmable’ mRNA drugs | BioPharma Dive
https://www.biopharmadive.com/news/strand-series-b-mrna-cancer-jake-becraft/757101/
